BC
IMNM icon

Birchview Capital’s Immunome IMNM Stock Holding History

Birchview Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Hold
50,000
– – 0.5% 41
2026
Q1 		$1.09M Sell
50,000
-80,000
-62% -$1.78M 0.62% 39
2025
Q4 		$2.79M Buy
130,000
+25,000
+24% +$439K 1.63% 19
2025
Q3 		$1.23M Buy
105,000
+45,000
+75% +$448K 0.93% 28
2025
Q2 		$558K Buy
+60,000
New +$492K 0.55% 41

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Birchview Capital's IMNM Position: Q2 2026 in Review

Birchview Capital held its Immunome (IMNM) position steady in Q2 2026 at 50,000 shares worth $1.06M. The position accounts for 0.5% of the portfolio, ranked #41.

Birchview Capital first reported a position in IMNM in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.79M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Birchview Capital held 50,000 shares of Immunome worth $1.06M as of Q2 2026.
  • Birchview Capital left its Immunome share count unchanged in Q2 2026.
  • Immunome made up 0.5% of Birchview Capital's portfolio in Q2 2026, its #41 holding.
  • Birchview Capital first reported a position in Immunome in Q2 2025 and has held it in 5 quarters since.
  • Birchview Capital's Immunome position peaked at $2.79M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.